The PSI Spin-Off Araris Biotech AG is one of the 10 winners of this year’s Venture Leaders Life Science award
As a winner, Araris will take part in the Swiss Biotech Day 2020 and a one-week roadshow to Boston, where Araris along with the other Venture Leaders will be pitching to key US investors and meeting leaders and experts of the biotech and medtech industries. Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion.
Swiss BIC of CERN Technologies calls for innovative ideas – deadline 30th April
For the third time, Switzerland Innovation Park Innovaare in Villigen/AG is hosting the call for proposals for high-tech business ideas that incorporate accelerator technologies into their products.
ANAXAM has Officially Launched
Anaxam is a technology transfer center created as a collaboration between PSI, the FHNW, the SNI and the Kanton of Aargau. Created to provide simplified access for industry to the large research facilities at PSI and focused on delivering services to support Advanced Manufacturing, both in the improvement of existing products as well as with manufacturing processes. ANAXAM has Officially Launched today 2019.12.01.
Park Innovaare: Groundbreaking Event
Today, PARK INNOVAARE steps into a new era. Accompanied by more than 200 guests including partners, shareholders, and key politicians, scientists and entrepreneurs, PARK INNOVAARE broke the ground to the construction of its new innovation campus. An investment of 155 CHF million by CPV/CAP Coop Pension Fund has brought this construction project to fruition
Araris Biotech AG closes seed financing round of CHF 2.5 million
Araris Biotech AG (a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich) announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs)
Park Innovaare: Financing of new Campus is secured
After an intensive round of negotiations, Park Innovaare concluded an investment agreement with CPV/CAP Pensionskasse Coop for the realization of the new buildings. With this agreement, Park Innovaare has come another step closer to realizing its goal: a state-of-the-art infrastructure of about 38’000 sqm next to the Paul Scherrer Institute PSI that is ideal for industrial R&D projects.
Congratulations to Debiopharm
Debiopharm – a Swiss pharma company that has licensed-in one of PSIs developments -a compound with high potential for cancer diagnosis & therapy has been nominated for the “2019/2020 Swiss Biotech Sucess Stories Awards”